Session I: Opening Session

Chair(s)

• 

  Eric Van Cutsem, MD, PhD

  University Hospital Gasthuisberg/Leuven
  Leuven, Belgium
• 

  Josep Tabernero, MD

  Vall d’Hebron University Hospital
  Barcelona, Spain
• 

  Michel Ducreux, MD, PhD

  Gustave Roussy
  Paris, France

Presentations:

• 13:05 – 13:15

  LBA O-9: Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
• 13:15 – 13:25

  LBA O-10: First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
  

  Abstract Presenter: Kei Muro, MD and PhD – Aichi Cancer Center Hospital
• 13:25 – 13:30

  Discussant: LBA 0-9, LBA 0-10
  

  Discussant: Ryan Corcoran, MD PhD – MGH Cancer Center